Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 3
1966 1
1970 1
1980 2
1987 1
1988 1
1989 1
1990 2
1991 3
1992 3
1993 2
1994 4
1995 2
1996 1
1997 1
1999 1
2000 3
2001 3
2002 2
2003 4
2005 2
2006 2
2008 5
2009 5
2010 1
2011 3
2012 6
2013 5
2014 6
2015 6
2016 11
2017 7
2018 14
2019 10
2020 8
2021 19
2022 24
2023 12

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Novel paradigms in systemic lupus erythematosus.
Dörner T, Furie R. Dörner T, et al. Among authors: furie r. Lancet. 2019 Jun 8;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-X. Epub 2019 Jun 6. Lancet. 2019. PMID: 31180031 Review.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Morand EF, et al. Among authors: furie r. N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. N Engl J Med. 2020. PMID: 31851795 Clinical Trial.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Furie R, et al. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. N Engl J Med. 2020. PMID: 32937045 Clinical Trial.
The immune cell landscape in kidneys of patients with lupus nephritis.
Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network. Arazi A, et al. Among authors: furie ra. Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17. Nat Immunol. 2019. PMID: 31209404 Free PMC article.
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P, Looney CM, Hassan I, Malvar A. Furie RA, et al. Ann Rheum Dis. 2022 Jan;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920. Epub 2021 Oct 6. Ann Rheum Dis. 2022. PMID: 34615636 Free PMC article. Clinical Trial.
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA. Rovin BH, et al. Among authors: furie r. Kidney Int. 2022 Feb;101(2):403-413. doi: 10.1016/j.kint.2021.08.027. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560137 Free article. Clinical Trial.
B cell-targeted therapies in systemic lupus erythematosus.
Arbitman L, Furie R, Vashistha H. Arbitman L, et al. Among authors: furie r. J Autoimmun. 2022 Oct;132:102873. doi: 10.1016/j.jaut.2022.102873. Epub 2022 Aug 11. J Autoimmun. 2022. PMID: 35963808 Review.
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Among authors: furie ra. Ann Rheum Dis. 2023 Oct 12:ard-2023-224762. doi: 10.1136/ard-2023-224762. Online ahead of print. Ann Rheum Dis. 2023. PMID: 37827694
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H. Kalunian KC, et al. Among authors: furie r. Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369793 Free PMC article. Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
173 results